Home / Pharmaceuticals / Small Animal Respiratory Diseases Treatment Market By Type Of Diseases (Allergic Pneumonitis, Canine Influenza, Canine Nasal Mites, Lung Nematodes, Neoplasia Of Respiratory System, Pneumonia, Rhinitis And Sinusitis, Tonsilitis), By Type Of Drug Class (Anthelmintics, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Antibiotics, Antihistamines, Phosphodiesterase (PDE) inhibitors, Bronchodilators, Antineoplastic Agents) - Growth, Future Prospects & Competitive Analysis, 2016 - 2024

Small Animal Respiratory Diseases Treatment Market By Type Of Diseases (Allergic Pneumonitis, Canine Influenza, Canine Nasal Mites, Lung Nematodes, Neoplasia Of Respiratory System, Pneumonia, Rhinitis And Sinusitis, Tonsilitis), By Type Of Drug Class (Anthelmintics, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Antibiotics, Antihistamines, Phosphodiesterase (PDE) inhibitors, Bronchodilators, Antineoplastic Agents) - Growth, Future Prospects & Competitive Analysis, 2016 - 2024

Published: Jan 2017 | Report Code: 58332-01-17

This report on global small animal respiratory diseases treatment market studies various type of diseases, drug class and geography. According to veterinary medical experts, upper respiratory infections– also called canine infectious respiratory disease (CIRD) is mainly caused in spaces occupied or visited by many pets such as boarding houses, groomers, and parks. These kind of infections are also known commonly as "Kennel Cough" because of the honking, dry sound made by infected animals, URI in pets is complex to diagnose because it can be caused by both bacteria or viruses and in most cases multiple agents are involved. These infections are highly contagious especially when dogs or cats get together in high-density situations such as pet stores and animal shelters the sanitization is the most important factor. 

For the purpose of this study, the various types of diseases considered are allergic pneumonitis, canine influenza, canine nasal mites, lung nematodes, neoplasia of respiratory system, pneumonia, rhinitis and sinusitis, tonsilitis, and others. Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The market segmentation on the basis types of drug class comprises sub-segments such as anthelmintics, NSAIDs, corticosteroids, antibiotics, antihistamines, phosphodiesterase (PDE) inhibitors, bronchodilators, antineoplastic agents, and others. Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The geographic segmentation of the global small animal respiratory diseases treatment market is performed for the regions North America, Europe, Asia-Pacific, Latin America and Middle East & Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The key players covered in small animal respiratory diseases treatment market are Zoetis, Inc., Merck Animal Health, Merial Inc. (Sanofi S.A), Boehringer Ingelheim GmbH, Elanco Animal Health (Eli Lilly), Bayer AG, Ceva Animal Health, Heska Corporation, Vetoquinol SA, Virbac Ltd., and Cipla Vet.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Small Animal Respiratory Diseases Treatment Market, by Type of Diseases, 2015 v/s 2024 (Value %)
2.2 Global Small Animal Respiratory Diseases Treatment Market, by Type of Drug Class, 2015 (USD Mn)
2.3 Global Small Animal Respiratory Diseases Treatment Market, by Geography, 2015 (Value %)

Chapter 3 Global Small Animal Respiratory Diseases Treatment Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising air pollution coupled with increasing obesity issues in pets
3.2.2 Lack of sanitization associated with pet shelter, pet stores and some households
3.2.3 Lack of sanitization associated with pet shelter, pet stores and some households
3.2.4 Increasing urban trend of having dogs and cats as pets accompanied with pet humanization
3.3 Market Restraints
3.3.1 Lack of public awareness associated with the veterinary respiratory disease symptoms and treatment
3.4 Market Opportunities
3.4.1 Small animal healthcare market growing significantly in Asia-Pacific and Middle East
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Small Animal Respiratory Diseases Treatment, by Key Players

Chapter 4 Global Small Animal Respiratory Diseases Treatment Market, By Type of Diseases
4.1 Overview
4.2 Allergic Pneumonitis
4.3 Canine Influenza
4.4 Canine Nasal Mites
4.5 Lung Nematodes
4.6 Neoplasia Of Respiratory System
4.7 Pneumonia
4.8 Rhinitis And Sinusitis
4.9 Tonsilitis
4.10 Other Respiratory Diseases (Tracheobronchitis, Lung Flukes, Pulmonary Thromboembolism, and Feline Respiratory Disease Complex)

Chapter 5 Global Small Animal Respiratory Diseases Treatment Market, By Type of Drug Class
5.1 Overview
5.2 Anthelmintics
5.3 Non-steroidal anti-inflammatory drugs (NSAIDs)
5.4 Corticosteroids
5.5 Antibiotics
5.6 Antihistamines
5.7 Phosphodiesterase (PDE) inhibitors
5.8 Bronchodilators
5.9 Antineoplastic Agents
5.10 Others (Beta Adrenergic Receptor Agonists, Anticoagulants, Antitussives and Immunosuppressants)

Chapter 6 Global Small Animal Respiratory Diseases Treatment Market, By Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K, Germany and Rest of Europe)
6.4 Asia Pacific (China, Japan and Rest of Asia-Pacific)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Zoetis, Inc.
7.1.1 Zoetis, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.2 Merck Animal Health
7.2.1 Merck Animal Health: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.3 Merial Inc. (Sanofi S.A)
7.3.1 Merial Inc. (Sanofi S.A): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.4 Boehringer Ingelheim GmbH
7.4.1 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.5 Elanco Animal Health (Eli Lilly)
7.5.1 Elanco Animal Health (Eli Lilly): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.6 Bayer AG
7.6.1 Bayer AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.7 Ceva Animal Health
7.7.1 Ceva Animal Health: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.8 Heska Corporation
7.8.1 Heska Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.9 Vetoquinol SA
7.9.1 Vetoquinol SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.10 Virbac Ltd.
7.10.1 Virbac Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.11 Cipla Vet
7.11.1 Cipla Vet: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Table :

TABLE 1 Market Competition Assessment: Precision Medicine , by Key Players
TABLE 2 Global Small Animal Respiratory Diseases Treatment Market, by Type of Diseases, 2014 - 2024 (USD Mn)
TABLE 3 Global Small Animal Respiratory Diseases Treatment Market, By Type of Drug Class, 2014-2024 (USD Mn)
TABLE 4 Global Small Animal Respiratory Diseases Treatment Market, by Geography, 2014 – 2024 (USD Mn)
TABLE 5 Zoetis, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 6 Merck Animal Health: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Merial Inc. (Sanofi S.A): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Elanco Animal Health (Eli Lilly): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Bayer AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 11 Ceva Animal Health: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 12 Heska Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 Vetoquinol SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Virbac Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 Cipla Vet: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Figure :

FIG. 1 Small Animal Respiratory Diseases Treatment Market: Research Methodology
FIG. 2 Global Small Animal Respiratory Diseases Treatment Market, by Type of Diseases, 2015 v/s 2024 (Value %)
FIG. 3 Global Small Animal Respiratory Diseases Treatment Market, by Type of Drug Class, 2015 (USD Mn)
FIG. 4 Global Small Animal Respiratory Diseases Treatment Market, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2015
FIG. 6 Global Allergic Pneumonitis Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 7 Global Canine Influenza Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 8 Global Canine Nasal Mites Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 9 Global Lung Nematodes Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 10 Global Neoplasia Of Respiratory System Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 11 Global Pneumonia Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 12 Global Rhinitis And Sinusitis Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 13 Global Tonsilitis Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 14 Global Other Respiratory Diseases Treatment Market in Small Animals, 2014 – 2024 (USD Mn)
FIG. 15 Anthelmintics Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 16 NSAIDs Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 17 Corticosteroids Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 18 Antibiotics Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 19 Antihistamines Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 20 Phosphodiesterase (PDE) inhibitors Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 21 Bronchodilators Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 22 Antineoplastic Agents Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 23 Other Drug Classes Market for Small Animal Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 24 North America Small Animal Respiratory Diseases Treatment Market , By Country, 2014 – 2024 (USD Mn)
FIG. 25 Europe Small Animal Respiratory Diseases Treatment Market , By Country, 2014 – 2024 (USD Mn)
FIG. 26 Asia-Pacific Small Animal Respiratory Diseases Treatment Market , By Country, 2014 – 2024 (USD Mn)
FIG. 27 Latin America Small Animal Respiratory Diseases Treatment Market , By Country, 2014 – 2024 (USD Mn)
FIG. 28 Middle East and Africa Small Animal Respiratory Diseases Treatment Market , 2014 – 2024 (USD Mn)

In May 2013, Small Animal CPD Meeting sponsored by Boehringer Ingelheim Vetmedica involved discussion with experts about the common symptoms observed in small animals such as coughing or dyspnoea with common disorders such as brachycephalic  syndrome, laryngeal paralysis, tracheal collapse, and feline asthma syndrome. Based on the type of respiratory diseases, the small animal respiratory diseases treatment market is segmented into:

  • Allergic Pneumonitis
  • Canine Influenza
  • Canine Nasal Mites
  • Lung Nematodes
  • Neoplasia of Respiratory System
  • Pneumonia
  • Rhinitis and Sinusitis
  • Tonsilitis
  • Others (Tracheobronchitis, Lung Flukes, Pulmonary Thromboembolism, and Feline Respiratory Disease Complex)

According to market experts, allergic pneumonitis, canine influenza, rhinitis and sinusitis and tonsillitis were observed as the most common respiratory diseases observed in small animals. According to American Veterinary Medical Foundation, the first recognized U.S. outbreak of H3N2 canine influenza occurred in 2015, starting in Chicago and spreading to other Midwestern states. Since March 2015, outbreaks have occurred in a number of areas throughout the U.S. and thousands of dogs have been confirmed positive for the H3N2 virus. It was observed that prevalence of canine influenza was also observed in cats and the displayed signs of upper respiratory disease including discharge, congestion, malaise, lip smacking and excessive salivation. Rhinitis and sinusitis are considered as the most infrequent problems in small animals but with changes occurring in environment with presence of air pollution and sudden environmental change may lead to chronic nasal diseases. The breed predilections for rhinitis and sinusitis comprised short-nose flat-faced cats that are more prone to chronic inflammation of the nose and most of the times fungal rhinitis. In case of dogs it is mainly observed in dogs with a long head and nose and these dogs are more prone to Aspergillus infection and nasal tumors. According to a research paper published by Daniel L. Hamilos in ATS Journals, ambient mold spores are widely distributed in nature, and an estimated 3 to 10% of the world's animal population is allergic to molds. The research study also suggests that compelling epidemiologic links between mold (fungal) allergy and illnesses such as asthma and asthma with allergic rhinitis. Fungal allergy is more prevalent in areas of high ambient mold spore concentrations. Hence, market dynamics of small animals respiratory diseases treatment involved the developing pet keeping trend in urban population mostly involving small animals, rising air pollution and abrupt environmental changes are affecting respiratory health of small animals, and maintenance of unsanitary conditions around pets also affect their respiratory system. 

Small Animal Respiratory Diseases Treatment Market

According to Royal Veterinary College, in U.K per 1000 dogs 23.2 dogs suffers with Kennel cough, 9.5 dogs suffer with coughing, 6.7 dogs are diagnosed with upper respiratory tract infection (URTI), and 3.9 dogs suffer with brachycephalic airway obstruction syndrome (BAOS). Based on the type of drug class, the small animal respiratory diseases treatment market is segmented into:

  • Anthelmintics
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
  • Antibiotics
  • Antihistamines
  • Phosphodiesterase (PDE) inhibitors
  • Bronchodilators
  • Antineoplastic Agents
  • Others (Beta Adrenergic Receptor Agonists, Anticoagulants, Antitussives and Immunosuppressants)

In 2015, it was observed that anthelmintics, corticosteroids and antibiotics accounted for more than 50% market share of the overall small animal respiratory diseases treatment market. According to market experts, most anthelmintics have wide safety margins, i.e., the dosage that can be given to an animal before adverse effects are induced is much higher than the dosage recommended for use. Thus, anthelmintics are prescribed very cautiously in small animals as the dose plays very critical role in the treatment of the diseases and anticipated side-effects. The most commonly used antibiotics in small animal respiratory diseases treatment are amoxicillin and cephalexin, sulfamethox, gentamicin, chloramphenicol, sulfadimethoxine, tetracycline, and doxycycline. The bacteria’s growth and further multiplication is inhibited by bacteriostatic antibiotics. Glucocorticoids through several mechanisms project the anti-inflammatory and immunosuppressive actions in the body that helps to overcome respiratory diseases in small animals.

Small Animal Respiratory Diseases Treatment Market

For the purpose of this study, the global small animal respiratory diseases treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Small Animal Respiratory Diseases Treatment Market

North America was observed as the largest market for small animal respiratory diseases treatment market due to factors such as rising air pollution, lack of sanitation related to pets in a few households, increasing urban trend of having dogs and cats as pets and rising awareness associated with the well-being of small animals. The European small animal respiratory diseases treatment market has displayed significant growth recently, albeit from a fairly low base compared to other regions. According to market experts, consumers in the region are more likely to own pets and provide them all the facilities as a family member. There is a noticeable inclination towards pet humanization, especially among young, urban and affluent consumers, and is expected to trade up to mid-priced or premium products. In 2015, Asia-Pacific was observed as the fastest growing small animal respiratory diseases treatment market due to key driving factors such as rising trend of keeping dogs and cats as pet in urban areas, increasing awareness in pet owners especially associated with several life-threatening diseases, and pet humanization trend is increasing rapidly in Asian countries.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients